New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin

Dalbavancin, an intravenous glycopeptide, was approved by the US Food and Drug Administration in May 2014 for use in adult patients with acute bacterial skin and skin structure infections. The recommended dosing regimen for effective use of dalbavancin is 1,000 mg followed by a 500 mg dose after 1 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Juul, Janelle J, Mullins, Caitlin F, Peppard, William J, Huang, Angela M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762434/
https://www.ncbi.nlm.nih.gov/pubmed/26937194
http://dx.doi.org/10.2147/TCRM.S71855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762434/
https://www.ncbi.nlm.nih.gov/pubmed/26937194
http://dx.doi.org/10.2147/TCRM.S71855

Ejemplares similares